Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome

Authors: Antoine Adenis, Emmanuelle Tresch, Sylvain Dewas, Olivier Romano, Mathieu Messager, Eric Amela, Stéphanie Clisant, Andrew Kramar, Christophe Mariette, Xavier Mirabel

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

To identify predictors of long-term outcome for patients with clinical complete response (cCR) after definite chemoradiotherapy (CRT) or radiation therapy (RT) for oesophageal cancer (EC).

Methods

In this retrospective study, we reviewed the files of all patients from our institution that underwent definitive RCT or RT for EC, from January 1998 to December 2003. Among 402 consecutive patients with EC, 110 cCR responses were observed, i.e. without evidence of tumour on morphological examination of the biopsy specimens, 8 to 10 weeks after radiation. Baseline patient and tumour characteristics were as follows: male = 98/110, median age = 60, squamous histology = 103/110, tumour site (upper/middle/lower third) = 41/50/19, weight loss none/<10%/≥10% = 36/45/29, dysphagia grade 1/2/≥3 = 30/14/66. Patients were staged according to endosonography and/or computed tomography. There were 9 stage I, 31 stage IIA, 15 stage IIB, 41 stage III, 6 stage IV. Post treatment nutritional characteristics were as follows: weight loss during treatment none/<10% ≥ 10% = 35/38/37, remaining dysphagia grade 1/2/≥3 = 54/24/32. Univariate and multivariate analyses were performed using log-rank and Cox proportional hazards models, and survival curves were estimated using the Kaplan-Meier method.

Results

During follow up (median: 6 [0.4–9.8] years), 16 patients had salvage surgery. Median OS was 2.5 years, and 5-year OS was 33.5%. Histological type, stage, age, gender, and treatment characteristics had no significant impact on outcome. The risk of death was increased two-fold for patients with grade ≥ 3 dysphagia after treament (HR = 1.9 [1.2–3.1], p = 0.007). Weight loss ≥10% during treatment also negatively affected outcome (HR = 1.8 [1.0–3.2], p = 0.040).

Conclusion

One EC patient among 3 with cCR after definite CRT/RT is still alive at 5 years. Variables related to reduced OS were: remaining significant dysphagia after treatment and weight loss ≥10% during treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRefPubMed
2.
go back to reference Faivre J, Forman D, Estève J, Obradovic M, Gatta G: Survival of patients with oesophageal and gastric cancers in Europe. Eur J Cancer. 1998, 34: 2167-2175. 10.1016/S0959-8049(98)00329-3.CrossRefPubMed Faivre J, Forman D, Estève J, Obradovic M, Gatta G: Survival of patients with oesophageal and gastric cancers in Europe. Eur J Cancer. 1998, 34: 2167-2175. 10.1016/S0959-8049(98)00329-3.CrossRefPubMed
3.
go back to reference Mariette C, Piessen G, Triboulet JP: Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007, 8: 545-553. 10.1016/S1470-2045(07)70172-9.CrossRefPubMed Mariette C, Piessen G, Triboulet JP: Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007, 8: 545-553. 10.1016/S1470-2045(07)70172-9.CrossRefPubMed
4.
go back to reference Mariette C, Piessen G, Briez N, Triboulet JP: The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008, 247: 365-371. 10.1097/SLA.0b013e31815aaadf.CrossRefPubMed Mariette C, Piessen G, Briez N, Triboulet JP: The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008, 247: 365-371. 10.1097/SLA.0b013e31815aaadf.CrossRefPubMed
5.
go back to reference Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992, 326: 1593-1598. 10.1056/NEJM199206113262403.CrossRefPubMed Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992, 326: 1593-1598. 10.1056/NEJM199206113262403.CrossRefPubMed
6.
go back to reference Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01): radiation therapy oncology group. JAMA. 1999, 281: 1623-1627. 10.1001/jama.281.17.1623.CrossRefPubMed Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01): radiation therapy oncology group. JAMA. 1999, 281: 1623-1627. 10.1001/jama.281.17.1623.CrossRefPubMed
7.
go back to reference Di Fiore F, Lecleire S, Pop D, Rigal O, Hamidou H, Paillot B, Ducrotté P, Lerebours E, Michel P: Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol. 2007, 102: 2557-2563. 10.1111/j.1572-0241.2007.01437.x.CrossRefPubMed Di Fiore F, Lecleire S, Pop D, Rigal O, Hamidou H, Paillot B, Ducrotté P, Lerebours E, Michel P: Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol. 2007, 102: 2557-2563. 10.1111/j.1572-0241.2007.01437.x.CrossRefPubMed
8.
go back to reference Lim JT, Truong PT, Berthelet E, Pai H, Joe H, Wai E, Larsson S, Kader HA, Weinerman B, Wilson K, Olivotto IA: Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2003, 57: 1328-1335. 10.1016/S0360-3016(03)00751-X.CrossRefPubMed Lim JT, Truong PT, Berthelet E, Pai H, Joe H, Wai E, Larsson S, Kader HA, Weinerman B, Wilson K, Olivotto IA: Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2003, 57: 1328-1335. 10.1016/S0360-3016(03)00751-X.CrossRefPubMed
9.
go back to reference Tahara M, Ohtsu A, Hironaka S, Ku N, Ishikura S, Miyata Y, Ogino T, Yoshida S: Clinical impact of criteria for complete response of primary site to treatment of esophageal cancer. Jpn J Clin Oncol. 2005, 35: 316-623. 10.1093/jjco/hyi095.CrossRefPubMed Tahara M, Ohtsu A, Hironaka S, Ku N, Ishikura S, Miyata Y, Ogino T, Yoshida S: Clinical impact of criteria for complete response of primary site to treatment of esophageal cancer. Jpn J Clin Oncol. 2005, 35: 316-623. 10.1093/jjco/hyi095.CrossRefPubMed
10.
go back to reference Michel P, Adenis A, Di Fiore F, Boucher E, Galais MP, Dahan L, Mirabel X, Hamidou H, Raoul JL, Jacob JH, Hellot MF, Prod'homme S, Paillot B: Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. Br J Cancer. 2006, 95: 705-709. 10.1038/sj.bjc.6603328.CrossRefPubMedPubMedCentral Michel P, Adenis A, Di Fiore F, Boucher E, Galais MP, Dahan L, Mirabel X, Hamidou H, Raoul JL, Jacob JH, Hellot MF, Prod'homme S, Paillot B: Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. Br J Cancer. 2006, 95: 705-709. 10.1038/sj.bjc.6603328.CrossRefPubMedPubMedCentral
11.
go back to reference Conroy T, Yataghene Y, Etienne PL, Michel P, Senellart H, Raoul JL, Mineur L, Rives M, Mirabel X, Lamezec B, Rio E, Le Prisé E, Peiffert D, Adenis A: Phase II randomized trial of definitive chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in first line treatment of patients with inoperable esophageal cancer. Br J Cancer. 2010, 103: 1349-1355. 10.1038/sj.bjc.6605943.CrossRefPubMedPubMedCentral Conroy T, Yataghene Y, Etienne PL, Michel P, Senellart H, Raoul JL, Mineur L, Rives M, Mirabel X, Lamezec B, Rio E, Le Prisé E, Peiffert D, Adenis A: Phase II randomized trial of definitive chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in first line treatment of patients with inoperable esophageal cancer. Br J Cancer. 2010, 103: 1349-1355. 10.1038/sj.bjc.6605943.CrossRefPubMedPubMedCentral
12.
go back to reference Brown WA, Thomas J, Gotley D, Burmeister BH, Lim KH, Martin I, Walpole ET, Thomson DB, Harvey JA, Smithers BM: Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg. 2004, 91: 199-204. 10.1002/bjs.4411.CrossRefPubMed Brown WA, Thomas J, Gotley D, Burmeister BH, Lim KH, Martin I, Walpole ET, Thomson DB, Harvey JA, Smithers BM: Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg. 2004, 91: 199-204. 10.1002/bjs.4411.CrossRefPubMed
13.
go back to reference Kalha I, Kaw M, Fukami N, Patel M, Singh S, Gagneja H, Cohen D, Morris J: The accuracy of endoscopic ultrasound for restaging esophageal carcinoma after chemoradiation therapy. Cancer. 2004, 101: 940-947. 10.1002/cncr.20429.CrossRefPubMed Kalha I, Kaw M, Fukami N, Patel M, Singh S, Gagneja H, Cohen D, Morris J: The accuracy of endoscopic ultrasound for restaging esophageal carcinoma after chemoradiation therapy. Cancer. 2004, 101: 940-947. 10.1002/cncr.20429.CrossRefPubMed
14.
go back to reference Westerterp M, van Westreenen HL, Reitsma JB, R Ansari H, Kasza K, Szeto L, Vokes EE: Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy -systematic review. Radiology. 2005, 236: 841-851. 10.1148/radiol.2363041042.CrossRefPubMed Westerterp M, van Westreenen HL, Reitsma JB, R Ansari H, Kasza K, Szeto L, Vokes EE: Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy -systematic review. Radiology. 2005, 236: 841-851. 10.1148/radiol.2363041042.CrossRefPubMed
15.
go back to reference Triboulet JP, Amrouni H, Guillem P, Vandenhaute B, Lecomte-Houcke M, Adenis A: Long term results of esophageal epidermoïd cancer with complete remeission to preoperative chemoradiotherapy. Ann Chir. 1998, 52: 503-508.PubMed Triboulet JP, Amrouni H, Guillem P, Vandenhaute B, Lecomte-Houcke M, Adenis A: Long term results of esophageal epidermoïd cancer with complete remeission to preoperative chemoradiotherapy. Ann Chir. 1998, 52: 503-508.PubMed
16.
go back to reference Schneider PM, Metzger R, Schaefer H, Baumgarten F, Vallbohmer D, Brabender J, Wolfgarten E, Bollschweiler E, Baldus SE, Dienes HP, Hoelscher AH: Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg. 2008, 248: 902-908. 10.1097/SLA.0b013e31818f3afb.CrossRefPubMed Schneider PM, Metzger R, Schaefer H, Baumgarten F, Vallbohmer D, Brabender J, Wolfgarten E, Bollschweiler E, Baldus SE, Dienes HP, Hoelscher AH: Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg. 2008, 248: 902-908. 10.1097/SLA.0b013e31818f3afb.CrossRefPubMed
17.
go back to reference Sarkaria IS, Rizk NP, Bains MS, Tang LH, Ilson DH, Minsky BI, Rusch VW: Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg. 2009, 249: 764-767. 10.1097/SLA.0b013e3181a38e9e.CrossRefPubMed Sarkaria IS, Rizk NP, Bains MS, Tang LH, Ilson DH, Minsky BI, Rusch VW: Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg. 2009, 249: 764-767. 10.1097/SLA.0b013e3181a38e9e.CrossRefPubMed
18.
go back to reference Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW, Trans-Tasman Radiation Oncology Group: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005, 9: 659-668.CrossRef Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW, Trans-Tasman Radiation Oncology Group: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005, 9: 659-668.CrossRef
19.
go back to reference Vallböhmer D, Hölscher AH, DeMeester S, DeMeester T, Salo J, Peters J, Lerut T, Swisher SG, Schröder W, Bollschweiler E, Hofstetter W: A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg. 2010, 252: 744-749. 10.1097/SLA.0b013e3181fb8dde.CrossRefPubMed Vallböhmer D, Hölscher AH, DeMeester S, DeMeester T, Salo J, Peters J, Lerut T, Swisher SG, Schröder W, Bollschweiler E, Hofstetter W: A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg. 2010, 252: 744-749. 10.1097/SLA.0b013e3181fb8dde.CrossRefPubMed
20.
go back to reference Ishihara R, Yamamoto S, Iishi H, Takeuchi Y, Sugimoto N, Higashino K, Uedo N, Tatsuta M, Yano M, Imai A, Nishiyama K: Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010, 76: 123-129. 10.1016/j.ijrobp.2009.01.038.CrossRefPubMed Ishihara R, Yamamoto S, Iishi H, Takeuchi Y, Sugimoto N, Higashino K, Uedo N, Tatsuta M, Yano M, Imai A, Nishiyama K: Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010, 76: 123-129. 10.1016/j.ijrobp.2009.01.038.CrossRefPubMed
21.
go back to reference Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, Takiuchi H, Komatsu Y, Miyata Y, Fukuda H, Gastrointestinal oncology study group of the Japan clinical oncology group (JCOG): Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011, 81: 684-690. 10.1016/j.ijrobp.2010.06.033.CrossRefPubMed Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, Takiuchi H, Komatsu Y, Miyata Y, Fukuda H, Gastrointestinal oncology study group of the Japan clinical oncology group (JCOG): Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011, 81: 684-690. 10.1016/j.ijrobp.2010.06.033.CrossRefPubMed
22.
go back to reference Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA: Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology. 2012, 82: 108-113. 10.1159/000335951.CrossRefPubMed Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA: Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology. 2012, 82: 108-113. 10.1159/000335951.CrossRefPubMed
23.
go back to reference Ellis FH, Heatley GJ, Balogh K: Proposal for improved staging criteria for carcinoma of the esophagus and cardia. Eur J Cardiothorac Surg. 1997, 12: 361-364. 10.1016/S1010-7940(97)00178-4.CrossRefPubMed Ellis FH, Heatley GJ, Balogh K: Proposal for improved staging criteria for carcinoma of the esophagus and cardia. Eur J Cardiothorac Surg. 1997, 12: 361-364. 10.1016/S1010-7940(97)00178-4.CrossRefPubMed
24.
go back to reference Mariette C, Maurel A, Fabre S, Balon JM, Triboulet JP: Preoperative prognostic factors for squamous cell carcinoma of the thoracic esophagus. Gastroenterol Clin Biol. 2001, 25: 468-472.PubMed Mariette C, Maurel A, Fabre S, Balon JM, Triboulet JP: Preoperative prognostic factors for squamous cell carcinoma of the thoracic esophagus. Gastroenterol Clin Biol. 2001, 25: 468-472.PubMed
25.
go back to reference O’Gilvie AL, Dronfield MW, Ferguson R, Atkinson M: Palliative intubation of esophagogastric neoplasms at fiberoptic endoscopy. Gut. 1982, 23: 1060-1067. 10.1136/gut.23.12.1060.CrossRef O’Gilvie AL, Dronfield MW, Ferguson R, Atkinson M: Palliative intubation of esophagogastric neoplasms at fiberoptic endoscopy. Gut. 1982, 23: 1060-1067. 10.1136/gut.23.12.1060.CrossRef
26.
go back to reference Adenis A, Francois E, Conroy T, Marchal C, Teissier E, Vedrenne B, Seitz JF, Mirabel X, Pignol JP, Resbeut M, Gyselinck N, Brandely M: Phase I study of vinorelbine and concurrent radiation for locally advanced esophageal cancer. ASCO Annual Meeting Proceedings. J Clin Oncol. 1999, 18: 271- Adenis A, Francois E, Conroy T, Marchal C, Teissier E, Vedrenne B, Seitz JF, Mirabel X, Pignol JP, Resbeut M, Gyselinck N, Brandely M: Phase I study of vinorelbine and concurrent radiation for locally advanced esophageal cancer. ASCO Annual Meeting Proceedings. J Clin Oncol. 1999, 18: 271-
27.
go back to reference Wider HA, Brücher BL, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ, Weber WA: Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004, 2: 900-908.CrossRef Wider HA, Brücher BL, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ, Weber WA: Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004, 2: 900-908.CrossRef
28.
go back to reference McLoughlin JM, Melis M, Seagel EM, Dean EM, Weber JM, Chern J, Elliott M, Kelley ST, Karl RC: Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer?. J Am Coll Surg. 2008, 206: 879-886. 10.1016/j.jamcollsurg.2007.12.027.CrossRefPubMed McLoughlin JM, Melis M, Seagel EM, Dean EM, Weber JM, Chern J, Elliott M, Kelley ST, Karl RC: Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer?. J Am Coll Surg. 2008, 206: 879-886. 10.1016/j.jamcollsurg.2007.12.027.CrossRefPubMed
29.
go back to reference Yang Q, Cleary KR, Yao JC, Swisher SG, Roth JA, Lynch PM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT: Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus. 2004, 17: 38-43. 10.1111/j.1442-2050.2004.00355.x.CrossRefPubMed Yang Q, Cleary KR, Yao JC, Swisher SG, Roth JA, Lynch PM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT: Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus. 2004, 17: 38-43. 10.1111/j.1442-2050.2004.00355.x.CrossRefPubMed
30.
go back to reference Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP: Phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002, 20: 1167-1174. 10.1200/JCO.20.5.1167.CrossRefPubMed Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP: Phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002, 20: 1167-1174. 10.1200/JCO.20.5.1167.CrossRefPubMed
31.
go back to reference Crosby TDL, Brewster AE, Borley A, Perschky L, Kehagioglou P, Court J, Maughan TS: Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer. 2004, 90: 70-75. 10.1038/sj.bjc.6601461.CrossRefPubMedPubMedCentral Crosby TDL, Brewster AE, Borley A, Perschky L, Kehagioglou P, Court J, Maughan TS: Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer. 2004, 90: 70-75. 10.1038/sj.bjc.6601461.CrossRefPubMedPubMedCentral
32.
go back to reference Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA: Failure patterns in patients with esophageal cancer with definite chemoradiation. Cancer. 2012, 118: 2632-2640. 10.1002/cncr.26586.CrossRefPubMed Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA: Failure patterns in patients with esophageal cancer with definite chemoradiation. Cancer. 2012, 118: 2632-2640. 10.1002/cncr.26586.CrossRefPubMed
33.
go back to reference Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the oesophagus: FFCD 9102. J Clin Oncol. 2007, 25: 1160-1168. 10.1200/JCO.2005.04.7118.CrossRefPubMed Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the oesophagus: FFCD 9102. J Clin Oncol. 2007, 25: 1160-1168. 10.1200/JCO.2005.04.7118.CrossRefPubMed
34.
go back to reference Jouve JL, Michel P, Mariette C, Bonnetain F, Bouché O, Conroy T, Pezet D, Burtin P, Segol P, Bedenne L: Fédération francophone de cancérologie digestive: outcome of the non randomized patients in the FFCD 9102 trial: chemo-radiation followed by surgery compared with chemo-radiation alone in squamous cancer of the esophagus: ASCO Annual Meeting Proceedings. J Clin Oncol. 2008, 26: A4555- Jouve JL, Michel P, Mariette C, Bonnetain F, Bouché O, Conroy T, Pezet D, Burtin P, Segol P, Bedenne L: Fédération francophone de cancérologie digestive: outcome of the non randomized patients in the FFCD 9102 trial: chemo-radiation followed by surgery compared with chemo-radiation alone in squamous cancer of the esophagus: ASCO Annual Meeting Proceedings. J Clin Oncol. 2008, 26: A4555-
35.
go back to reference Mariette C, De Botton ML, Piessen G: Surgery in esophageal and gastric cancer patients: what is the role for nutrition support in your daily practice?. Ann Surg Oncol. 2012, 19: 2128-2134. 10.1245/s10434-012-2225-6.CrossRefPubMed Mariette C, De Botton ML, Piessen G: Surgery in esophageal and gastric cancer patients: what is the role for nutrition support in your daily practice?. Ann Surg Oncol. 2012, 19: 2128-2134. 10.1245/s10434-012-2225-6.CrossRefPubMed
Metadata
Title
Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome
Authors
Antoine Adenis
Emmanuelle Tresch
Sylvain Dewas
Olivier Romano
Mathieu Messager
Eric Amela
Stéphanie Clisant
Andrew Kramar
Christophe Mariette
Xavier Mirabel
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-413

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine